Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-Lymphoma

Sponsor
University of Magdeburg
Study ID
NCT00384553
Phase
PHASE1/PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Rituximab — DRUG
  • DHAP — DRUG
  • TEC — DRUG
  • autologous stem cell transplantation — DRUG

Study Details

This study investigates toxicity and efficacy of 2 x R-DHAP followed by High dose chemotherapy R-TEC and autologous stem cell transplantation in patients with relapsed or refractory aggressive Non- Hodgkins's Lymphoma.

Key Dates

Start date
Jun 30, 2004
Status verified
Oct 2006
Completion
Jun 30, 2010

Study Design

Enrollment
30 participants
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Toxicity

Central Contacts

  • Michael Koenigsmann, PD Dr. med
    +4939113281

Related Studies